Eli Lilly Receives FDA Approval for New Weight-Loss Drug Zepbound, a Version of Diabetes Treatment Mounjaro
This medication, also known as tirzepatide, demonstrated significant weight loss potential, with dieters shedding between 40 to 60 pounds in trials. Eli Lilly has received approval from the U.S. Food and Drug Administration for its new weight-loss drug, Zepbound, a version of the well-known diabetes treatment Mounjaro Eli Lilly’s Zepbound joins Novo Nordisk’s Wegovy as … Read more